RNA nanomedicines: the next generation drugs?

Singh, Manu Smriti; Peer, Dan

doi:10.1016/j.copbio.2015.12.011

Cited by 33 publications

(18 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been observed that silencing genes such as B-cell lymphoma 2 (BCL2) and BCL-xL sensitizes cisplatin-resistant cells (16,17). RNA therapeutics, the design and dosage of which can be tailored to individual patients based on their mRNA expression levels of target genes, might represent the next generation of personalized medicine (18).…”

mentioning

confidence: 99%

shRNA-WT1 Potentiates Anticancer Effects of Gemcitabine and Cisplatin Against B16F10 Lung MetastasesIn VitroandIn Vivo

Zapata‐Benavides¹,

Thompson-Armendariz²,

Arellano-Rodríguez³

et al. 2019

In Vivo

View full text Add to dashboard Cite

Background/Aim: High expression level of Wilm's tumor gene (WT1) in several types of tumors appears to confer disruption of apoptosis and resistance to chemotherapeutic drugs, and correlate with poor outcome. The aim of this work was to determine if down-regulation of WT1 expression results in decreased cell proliferation and the increased action of different types of drugs, both in vitro in B16F10 cells, and in vivo in C57BL/6 mice. Materials and Methods: Inhibition of cell proliferation by short hairpin RNA against WT1 (shRNA-WT1), cisplatin, and gemcitabine in B16F10 cells in vitro was determined by the MTT assay and analysis of clonogenic survival. The apoptosis rate was determined by flow cytometry for annexin-V-fluorescein isothiocyante and propidium iodide. Results: Compared to treatment with shRNA-WT1 alone, treatment with shRNA-WT1 in combination with drugs had a synergistic inhibitory effect on B16F10 cell proliferation, particularly for the combination of cisplatin and gemcitabine at their 25% cytotoxic concentrations in vitro. Furthermore, mice treated with shRNA-WT1 in combination with cisplatin and gemcitabine were protected in the same way as those treated with the drugs alone, but were in better physical condition. Conclusion: Decreased WT1 expression induces cell death and potentiates the action of anticancer drugs by inducing synergistic effects both in vitro and in vivo, which may be an attractive strategy in lung cancer therapy.

show abstract

mentioning

confidence: 99%

shRNA-WT1 Potentiates Anticancer Effects of Gemcitabine and Cisplatin Against B16F10 Lung MetastasesIn VitroandIn Vivo

Zapata‐Benavides¹,

Thompson-Armendariz²,

Arellano-Rodríguez³

et al. 2019

In Vivo

View full text Add to dashboard Cite

show abstract

“…Recently, the star polymers for siRNA delivery were designed. These delivery materials [189]. The other additional systems include siRNA trial using a targeted fourcomponent polymer NP (CALAA-01) for melanoma cancer therapy using a cationized cyclodextrin, adamantane-PEG, adamantane-PEG-transferrin targeted delivery, and the siRNA delivery system.…”

Section: Nanoparticle Delivery Of Sirna For Therapeutic Applicationsmentioning

confidence: 99%

Nanoparticles for radiooncology: Mission, vision, challenges

et al. 2017

View full text Add to dashboard Cite

Cancer is one of the leading non-communicable diseases with highest mortality rates worldwide. About half of all cancer patients receive radiation treatment in the course of their disease. However, treatment outcome and curative potential of radiotherapy is often impeded by genetically and/or environmentally driven mechanisms of tumor radioresistance and normal tissue radiotoxicity. While nanomedicine-based tools for imaging, dosimetry and treatment are potential keys to the improvement of therapeutic efficacy and reducing side effects, radiotherapy is an established technique to eradicate the tumor cells. In order to progress the introduction of nanoparticles in radiooncology, due to the highly interdisciplinary nature, expertise in chemistry, radiobiology and translational research is needed. In this report recent insights and promising policies to design nanotechnology-based therapeutics for tumor radiosensitization will be discussed. An attempt is made to cover the entire field from preclinical development to clinical studies. Hence, this report illustrates (1) the radio- and tumor-biological rationales for combining nanostructures with radiotherapy, (2) tumor-site targeting strategies and mechanisms of cellular uptake, (3) biological response hypotheses for new nanomaterials of interest, and (4) challenges to translate the research findings into clinical trials.

show abstract

“…3,30) In particular, siRNA-based therapy has demonstrated promising outcomes in clinical trials. 3,[31][32][33] In order to realize the optimum effects of siRNA-based therapy, efficient in vivo siRNA delivery into the cytoplasm of target cells in target organs is required. However, due to siRNA's distinct physi- cochemical and biological properties, such as relatively large molecular weight, hydrophilicity, anionic charge, instability in the bloodstream, immune response activation and rapid clearance, 3,34,35) various hurdles stand in the way of effective in vivo siRNA delivery.…”

Section: Recent Advances In Oligonucleotide-based Therapy In Attr-fapmentioning

confidence: 99%

Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects

Hayashi

Jono

2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Transthyretin (TTR) amyloidosis, also known as transthyretin-related familial amyloidotic polyneuropathy (ATTR-FAP), is a fatal hereditary systemic amyloidosis caused by mutant forms of TTR. Although conventional treatments for ATTR-FAP, such as liver transplantation (LT) and TTR tetramer stabilizer, reportedly halt the progression of clinical manifestation, these therapies have several limitations. Oligonucleotide-based therapy, e.g. small interfering RNA (siRNA)-and antisense oligonucleotides (ASOs)-based therapy, hold enormous potential for the treatment of intractable diseases such as ATTR-FAP, by specifically regulating the gene responsible for the disease. Clinical evidence strongly suggests that LT inhibits mutant TTR production, thus improving the manifestation of ATTR-FAP. Therefore, an oligonucleotide-based therapy for ATTR-FAP, which reduces the production of TTR by the liver, has recently been developed in preclinical and clinical studies. This review focuses on recent advances in oligonucleotide-based therapy and future prospects of next-generation oligonucleotide-based drugs for therapeutic use against ATTR-FAP.

show abstract

RNA nanomedicines: the next generation drugs?

Cited by 33 publications

References 58 publications

shRNA-WT1 Potentiates Anticancer Effects of Gemcitabine and Cisplatin Against B16F10 Lung MetastasesIn VitroandIn Vivo

shRNA-WT1 Potentiates Anticancer Effects of Gemcitabine and Cisplatin Against B16F10 Lung MetastasesIn VitroandIn Vivo

Nanoparticles for radiooncology: Mission, vision, challenges

Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects

Contact Info

Product

Resources

About